Air Liquide stock holds its ground as 2025 sales reach EUR 27.06 billion

Air Liquide stock tracks a 2025 sales base of EUR 27.06 billion, with Industrial Merchant sales up 2.2% and Healthcare sales up 5.5% for the full year.

Air Liquide stock holds a 2025 sales base of EUR 27.06 billion, while the group reported Industrial Merchant sales up 2.2% and Healthcare sales up 5.5% for the full year. The company (FR0000120073) remains anchored by a large recurring revenue mix, and its latest investor materials provide the clearest read on the current setup.

Sales base of EUR 27.06 billion

Air Liquide reported 2025 sales of EUR 27.06 billion, a period that also showed a 2.2% increase in Industrial Merchant sales and a 5.5% rise in Healthcare sales. Those two divisions matter because they provide day-to-day visibility across industrial demand and medical gases, which together shape the group’s cash generation profile.

The number that stands out for investors is the scale of the base itself: EUR 27.06 billion in 2025 sales is a large foundation for a business that depends more on recurring volumes and pricing than on one-off orders. That makes the segment mix as important as the top line, especially when one division is expanding faster than the other.

Healthcare growth at 5.5%

Healthcare sales rose 5.5% in 2025, outpacing Industrial Merchant growth of 2.2% over the same period. That gap suggests the medical-gas and home healthcare business kept a steadier growth profile than the more cyclical merchant gases division.

For Air Liquide, that kind of split matters because it shows where the company is finding momentum inside the portfolio. A 5.5% rise in one core division is not just a rounding detail; it is a useful signal for how the group balances cyclical and defensive demand.

What the mix says

Industrial Merchant remains a central earnings driver, but the 2.2% full-year increase was slower than Healthcare’s 5.5% advance. That comparison is useful because it shows the company is not relying on one line of business alone to carry growth.

The broader takeaway from the 2025 figures is that Air Liquide enters the current market period with a large revenue base, a defensive healthcare engine, and enough industrial exposure to benefit when activity improves. The mix, rather than a single headline number, is what investors are likely to watch most closely in the next update.

Investor materials on the group

Air Liquide’s investor information remains the most direct source for its recurring sales profile and segment detail, and the figures above come from that 2025 reporting context. The company’s business is also easier to read than many industrial peers because Healthcare and Industrial Merchant provide separate lenses on demand and pricing.

That matters when markets look for evidence that growth is broad enough to endure. A 5.5% rise in Healthcare alongside 2.2% in Industrial Merchant is a cleaner picture than a single headline revenue figure would provide.

Air Liquide stock closing level

Air Liquide stock is best framed today through its 2025 operating base rather than a quoted price, since the latest verified market level is not present in the source set. The useful reference point is EUR 27.06 billion in 2025 sales, paired with 2.2% Industrial Merchant growth and 5.5% Healthcare growth.

Air Liquide at a glance

• Company: Air Liquide S.A.
• ISIN: FR0000120073
• Ticker: Euronext Paris: AI
• Trading venue: Euronext Paris
• Sector / Industry: Materials / Industrial Gases
• Index membership: CAC 40